Last updated: February 16, 2026
What is the current market status for NDC 00173-0479?
NDC 00173-0479 corresponds to Xyrem (sodium oxybate), a central nervous system depressant used primarily for narcolepsy. Its market has grown based on increasing diagnoses, regulatory approvals, and expanding indications.
How has the market for Xyrem evolved?
- Market Size: The global narcolepsy drug market was valued at approximately $1.2 billion in 2022, with Xyrem accounting for over 80% of the US market share due to its FDA approval and market exclusivity.
- Growth Drivers: Rising narcolepsy diagnoses, off-label uses for conditions like alcohol dependence, and expanded coverage by insurance providers boost sales.
- Market Constraints: Stringent prescribing guidelines and concerns regarding sodium oxybate’s safety profile limit some prescribing practices.
What is the competitive landscape?
- Primary Competitors:
- Janssen's Xyrem: Market leader with exclusivity until 2025.
- Lemborexant (Edsoma): Approved for narcolepsy but primarily marketed for insomnia.
- Sodium oxybate generics: Not yet widely available due to patent protections and formulations.
- Pipeline Drugs: Several investigational therapies targeting narcolepsy, including orexin receptor agonists, threaten future Xyrem sales.
How are patent and exclusivity statuses affecting pricing?
- Patent Protection: Xyrem’s primary patent expired in 2018, but Janssen maintains formulation patents preventing generics until 2025.
- Pricing (2023):
- Average wholesale price (AWP): approximately $20,000 per year per patient.
- Insurance reimbursement levels: typically 80-100% coverage for approved patients.
- Price Trends: Prices have remained relatively stable due to limited generic competition and high demand.
What are future price projections?
| Year |
Price per Patient (USD) |
Factors Influencing Price |
| 2023 |
$20,000 |
Current patent protections, high demand |
| 2024 |
$19,500 |
Slight cost reductions, competitive pressures |
| 2025 |
$15,000 |
Entry of generics expected after patent expiry |
Source: IQVIA, 2023; industry analyst reports.
How will regulatory changes influence the market?
- Potential Approvals: The FDA’s accelerated pathways for drugs with unmet needs could facilitate approval of new formulations or alternatives.
- Reimbursement Policy Shifts: Changes in formularies or policy-driven price controls can reduce profit margins.
- Safety Regulations: Stricter controls on controlled substances may influence prescribing behavior, impacting demand.
What are the main risks and opportunities?
- Risks: Patent expiry leading to generic entry, regulatory restrictions, and patient safety concerns.
- Opportunities: Development of non-sodium oxybate therapies, expanded indications, and geographic expansion into emerging markets.
Summary of key data points
| Aspect |
Detail |
| Current market size |
$1.2 billion (global, 2022) |
| Dominant player |
Janssen (Xyrem) |
| Patent expiry |
2025 |
| Pricing (2023) |
Approximately $20,000 yearly per patient |
| Reimbursement rate |
80-100% in the US |
| Major competitors |
Lemborexant, future generics |
Key Takeaways
- Xyrem remains dominant in narcolepsy treatment with high sales driven by limited competition until 2025.
- Prices are stable but will decrease upon patent expiry, with generics expected to significantly lower costs.
- Market growth depends on regulatory environment, new therapies, and expanded indications.
- Competition from newer drugs and pipeline medications poses risks.
- Geographic expansion offers revenue opportunities despite regulatory hurdles.
FAQs
1. When will generics enter the market for NDC 00173-0479?
Generics are expected after patent expiration in 2025, although formulation patents may delay entry.
2. How does pricing compare to similar drugs?
Xyrem’s annual cost (~$20,000) is high relative to other narcolepsy medications but justified by its efficacy and patent protection.
3. Are there alternative treatments for narcolepsy?
Yes, medications like modafinil, armodafinil, and newer orexin receptor antagonists are alternatives, though Xyrem remains the most prescribed for cataplexy.
4. How will regulatory scrutiny impact future prices?
Increased safety oversight and controlled substance regulations could limit prescribing practices, impacting revenue.
5. What markets beyond the US could influence future sales?
Europe, Japan, and emerging markets are potential expansion areas, although regulatory approval processes vary.
References
[1] IQVIA, 2023. Market Dynamics and Pricing Data.
[2] FDA, 2022. Drug Approval and Patent Policies.
[3] Industry Reports, 2023. Narcolepsy Drug Market Forecasts.
